Gene Transfer of Huctla4-Ig to Inhibit the Acute Rejection of Liver Allograft in Rats

朱斌,杨甲梅,钱其军,王孟龙,崔贞福,李玲芳,吴孟超

DOI: https://doi.org/10.3760/cma.j.issn.0254-1785.2005.04.002

2005-01-01

Abstract:Objective To observe the effect of gene transfer of huCTLA4-Ig to inhibit the acute rejection of liver allograft in rats. Methods With AdEasy vector system, the recombinant adenovirus containing huCTLA4-Ig gene was constructed. Using ex vivo gene transfer technique, exogenous gene was introduced to the liver graft during cold preservation and expressed locally in the graft. The effect of inhibition of acute rejection and inducing liver graft tolerance was observed. Results No recipients in group A (without any treatment, n = 5) or group B (treated with Ad-GFP, n - 4) died within 3 weeks after transplantation and severe acute rejection (massive periportal infiltration, endothelilitis, damage to biliary epithelium and severe tissue destruction) was confirmed pathologically in the graft. In contrast, all recipients in group C (treated with Ad-huCTLA4-Ig, n- 5) achieved long-term liver allograft survival (150 days). Histological examination of Ad-huCTLA4-Ig transduced allografts demonstrated a mild to moderate periportal inflammation and mild injury to liver graft on day 8 postt-ransplant. A mild mononuclear infiltration was observed; however, there was complete preservation of the bile ducts and no evidence of vascular injury on day 150 posttransplant. The mean IL-2 concentration in serum was (362. 09±45. 84)ng/L on day 1 pretransplant. In control animals (groups A and B), serum IL-2 concentration was elevated to a high level within 7 days posttransplant, which was a-bout 1.5 to 2. 5 times as much as that before transplant. In contrast, in huCTLA4-Ig-treated animals (group C), IL-2 concentration in serum was maintained at a relative low level, which was near or less than that before transplant (P0. 01). Conclusions Using ex vivo gene transfer technique, huCTLA4-Ig gene can be introduced to the liver graft during cold preservation. The modified graft can express and excrete immunoregulatory protein locally, which can suppress acute alloimmune response and is re sponsible for prolongation of graft survival without using routine immunosuppressive drugs. These findings provide some experimental evidence that gene delivery of sequences encoding immunoregulatory proteins can be applied in clinical liver transplantation for inhibiting the acute alloimmune response and achieving graft tolerance.